1. Home
  2. MEGI vs CTMX Comparison

MEGI vs CTMX Comparison

Compare MEGI & CTMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MainStay CBRE Global Infrastructure Megatrends Term Fund

MEGI

MainStay CBRE Global Infrastructure Megatrends Term Fund

HOLD

Current Price

$14.57

Market Cap

788.0M

Sector

Finance

ML Signal

HOLD

Logo CytomX Therapeutics Inc.

CTMX

CytomX Therapeutics Inc.

HOLD

Current Price

$3.29

Market Cap

716.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MEGI
CTMX
Founded
N/A
2008
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
788.0M
716.9M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
MEGI
CTMX
Price
$14.57
$3.29
Analyst Decision
Strong Buy
Analyst Count
0
10
Target Price
N/A
$12.10
AVG Volume (30 Days)
112.7K
3.0M
Earning Date
01-01-0001
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$76,201,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$7.61
P/E Ratio
N/A
$22.58
Revenue Growth
N/A
N/A
52 Week Low
$13.42
$1.90
52 Week High
$15.89
$8.21

Technical Indicators

Market Signals
Indicator
MEGI
CTMX
Relative Strength Index (RSI) 36.97 46.66
Support Level $13.44 $3.17
Resistance Level $15.45 $3.57
Average True Range (ATR) 0.22 0.19
MACD -0.02 0.01
Stochastic Oscillator 9.72 29.37

Price Performance

Historical Comparison
MEGI
CTMX

About MEGI MainStay CBRE Global Infrastructure Megatrends Term Fund

NYLI CBRE Global Infrastructure Megatrends Term Fund is a non-diversified, closed-end management investment company. The Fund's investment objective is to seek a high level of total return with an emphasis on current income. It is focused on the investment megatrends of decarbonization, digital transformation and asset modernization, which are reshaping the demand for infrastructure assets and driving income and growth potential.

About CTMX CytomX Therapeutics Inc.

CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

Share on Social Networks: